$KPTI
Karyopharm Therapeutics Inc.

2015 Q3 Form 10-Q Financial Statement

#000119312515283822 Filed on August 10, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q2
Revenue $75.00K $150.0K $21.00K
YoY Change 257.14% 614.29% -84.21%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.760M $6.160M $3.310M
YoY Change 24.93% 86.1% 252.13%
% of Gross Profit
Research & Development $25.92M $27.01M $13.16M
YoY Change 62.52% 105.23% 117.15%
% of Gross Profit
Depreciation & Amortization $170.0K $150.0K $50.00K
YoY Change 70.0% 200.0% 25.0%
% of Gross Profit
Operating Expenses $30.69M $33.16M $16.47M
YoY Change 55.25% 101.37% 135.17%
Operating Profit -$30.61M -$33.01M -$16.45M
YoY Change 55.03% 100.71% 139.42%
Interest Expense $240.0K $270.0K $20.00K
YoY Change 1100.0% 1250.0%
% of Operating Profit
Other Income/Expense, Net $237.0K $318.0K $17.00K
YoY Change 1085.0% 1770.59% 1600.0%
Pretax Income -$30.37M -$32.70M -$16.43M
YoY Change 54.01% 99.03% 139.16%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$30.37M -$32.70M -$16.43M
YoY Change 53.99% 98.98% 139.17%
Net Earnings / Revenue -40497.33% -21796.67% -78242.86%
Basic Earnings Per Share
Diluted Earnings Per Share -$850.5K -$916.0K -$553.9K
COMMON SHARES
Basic Shares Outstanding 35.71M shares 35.69M shares 29.76M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $195.2M $221.2M $132.3M
YoY Change -14.05% 67.2% 647.46%
Cash & Equivalents $43.50M $24.23M $132.3M
Short-Term Investments $151.7M $197.0M
Other Short-Term Assets $3.100M $4.100M $3.000M
YoY Change -26.19% 36.67% 500.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $198.3M $225.3M $135.3M
YoY Change -14.27% 66.5% 643.31%
LONG-TERM ASSETS
Property, Plant & Equipment $3.660M $3.234M $604.0K
YoY Change 33.87% 435.43% 101.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $34.40M $34.40M
YoY Change
Other Assets $52.00K $400.0K $1.392M
YoY Change -92.3% -71.26%
Total Long-Term Assets $38.63M $38.04M $2.396M
YoY Change 914.1% 1487.69% 698.67%
TOTAL ASSETS
Total Short-Term Assets $198.3M $225.3M $135.3M
Total Long-Term Assets $38.63M $38.04M $2.396M
Total Assets $237.0M $263.3M $137.7M
YoY Change 0.77% 91.24% 644.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.568M $4.469M $3.456M
YoY Change 117.32% 29.31% 103.29%
Accrued Expenses $9.469M $9.333M $2.003M
YoY Change 159.5% 365.95% 150.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.44M $14.10M $5.647M
YoY Change 131.63% 149.67% 125.88%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.900M $1.900M $151.0K
YoY Change 72.73% 1158.28%
Total Long-Term Liabilities $1.900M $1.900M $151.0K
YoY Change 72.73% 1158.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.44M $14.10M $5.647M
Total Long-Term Liabilities $1.900M $1.900M $151.0K
Total Liabilities $16.38M $15.97M $5.999M
YoY Change 122.81% 166.14% 139.96%
SHAREHOLDERS EQUITY
Retained Earnings -$227.5M -$197.1M
YoY Change
Common Stock $448.1M $444.6M $3.000K
YoY Change 14936533.33% 14819166.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $220.6M $247.3M $131.7M
YoY Change
Total Liabilities & Shareholders Equity $237.0M $263.3M $137.7M
YoY Change 0.77% 91.24% 644.21%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$30.37M -$32.70M -$16.43M
YoY Change 53.99% 98.98% 139.17%
Depreciation, Depletion And Amortization $170.0K $150.0K $50.00K
YoY Change 70.0% 200.0% 25.0%
Cash From Operating Activities -$25.33M -$28.09M -$11.88M
YoY Change 56.07% 136.45% 93.17%
INVESTING ACTIVITIES
Capital Expenditures -$140.0K -$590.0K -$320.0K
YoY Change -93.89% 84.38%
Acquisitions
YoY Change
Other Investing Activities $44.69M $1.450M $0.00
YoY Change
Cash From Investing Activities $44.55M $860.0K -$320.0K
YoY Change -2045.41% -368.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.00K 20.00K -380.0K
YoY Change -99.96% -105.26% -101.65%
NET CHANGE
Cash From Operating Activities -25.33M -28.09M -11.88M
Cash From Investing Activities 44.55M 860.0K -320.0K
Cash From Financing Activities 40.00K 20.00K -380.0K
Net Change In Cash 19.26M -27.21M -12.58M
YoY Change -79.69% 116.3% -174.39%
FREE CASH FLOW
Cash From Operating Activities -$25.33M -$28.09M -$11.88M
Capital Expenditures -$140.0K -$590.0K -$320.0K
Free Cash Flow -$25.19M -$27.50M -$11.56M
YoY Change 80.7% 137.89% 87.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
3681 sqft
CY2014Q4 kpti Operating Lease Scheduled Rent Payments Due
OperatingLeaseScheduledRentPaymentsDue
374000
CY2014Q4 kpti Operating Lease Scheduled Rent Payments Due
OperatingLeaseScheduledRentPaymentsDue
415000
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35711150 shares
CY2014Q1 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
29933 sqft
CY2014Q1 us-gaap Security Deposit
SecurityDeposit
400000
CY2014Q1 kpti Security Deposit Which May Be Reduced In Future
SecurityDepositWhichMayBeReducedInFuture
200000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
132307000
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35703418 shares
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q2 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
64 Securities
CY2015Q2 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 Securities
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35703418 shares
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
444574000
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
241000
CY2015Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1995000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
247327000
CY2015Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
260000
CY2015Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
200000
CY2015Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
97000
CY2015Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1867000
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
38000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4469000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9333000
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197108000
CY2015Q2 us-gaap Liabilities
Liabilities
15966000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
263293000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
4000
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
784000
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
14099000
CY2015Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-143000
CY2015Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
231362000
CY2015Q2 us-gaap Assets
Assets
263293000
CY2015Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
102000
CY2015Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
244983000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3234000
CY2015Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
400000
CY2015Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
116237000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
225252000
CY2015Q2 us-gaap Tenant Improvements
TenantImprovements
568000
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4066000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24231000
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4018000
CY2015Q2 us-gaap Short Term Investments
ShortTermInvestments
196955000
CY2015Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
231362000
CY2015Q2 us-gaap Long Term Investments
LongTermInvestments
34407000
CY2015Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
231426000
CY2015Q2 kpti Operating Lease Property Leased Area Covered Under Amended Agreement
OperatingLeasePropertyLeasedAreaCoveredUnderAmendedAgreement
27701 sqft
CY2015Q2 kpti Additional Area Included In Operating Sublease After Amendment
AdditionalAreaIncludedInOperatingSubleaseAfterAmendment
16234 sqft
CY2015Q2 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6837000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
155974000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32699380 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
11 Securities
CY2014Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 Securities
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32699380 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
345166000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
309000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1568000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
206794000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
324000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
126000
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
62000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1242000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6288000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5825000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-138346000
CY2014Q4 us-gaap Liabilities
Liabilities
13543000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
220337000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
494000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12301000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-29000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
63773000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
774000
CY2014Q4 us-gaap Assets
Assets
220337000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
25000
CY2014Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
192982000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2754000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
400000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
12635000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
207751000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2027000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
150609000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3248000
CY2014Q4 us-gaap Short Term Investments
ShortTermInvestments
55115000
CY2014Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
63773000
CY2014Q4 us-gaap Long Term Investments
LongTermInvestments
8658000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
63795000
CY2014Q4 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3624000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-22451000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.02
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29633215 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
449000
us-gaap Net Income Loss
NetIncomeLoss
-30125000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30125000
us-gaap Sales Revenue Net
SalesRevenueNet
193000
us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-223000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
994000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
427000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30159000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
34000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
645000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
400000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30125000
us-gaap Investment Income Interest
InvestmentIncomeInterest
34000
us-gaap Share Based Compensation
ShareBasedCompensation
6734000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-43000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
151000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-23667000
us-gaap Operating Expenses
OperatingExpenses
30352000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-849000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-367000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24138000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
629000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
60000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6214000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1685000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
85000
kpti Restricted Shares Common Stock Vested Value
RestrictedSharesCommonStockVestedValue
77000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-48324000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.65
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001503802
dei Trading Symbol
TradingSymbol
KPTI
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35508146 shares
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
KARYOPHARM THERAPEUTICS INC.
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
774000
us-gaap Net Income Loss
NetIncomeLoss
-58762000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-58762000
us-gaap Sales Revenue Net
SalesRevenueNet
150000
us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-699000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2038000
us-gaap Operating Income Loss
OperatingIncomeLoss
-59163000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
401000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
209517000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-816000
us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
52000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-774000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-42000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58877000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-73000
us-gaap Investment Income Interest
InvestmentIncomeInterest
408000
us-gaap Share Based Compensation
ShareBasedCompensation
8231000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
464000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-126378000
us-gaap Operating Expenses
OperatingExpenses
59313000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-169222000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
41069000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
91177000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47757000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-9000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3446000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
347000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11556000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1782000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
292000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
7000
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32857000
kpti Restricted Shares Common Stock Vested Value
RestrictedSharesCommonStockVestedValue
84000
kpti Operating Leases Allowance For Improvements
OperatingLeasesAllowanceForImprovements
1616000
kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
-90830000
CY2014Q4 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P5Y
CY2014Q1 kpti Lessee Leasing Arrangements Operating Leases Additional Extension Term
LesseeLeasingArrangementsOperatingLeasesAdditionalExtensionTerm
P5Y
CY2014Q1 kpti Number Of Additional Lease Terms Option To Renew
NumberOfAdditionalLeaseTermsOptionToRenew
1 Lease
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29659457 shares
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-16431000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16431000
CY2014Q2 us-gaap Sales Revenue Net
SalesRevenueNet
21000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16448000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17000
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16431000
CY2014Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
17000
CY2014Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
104000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
16469000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13159000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3310000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.92
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35697012 shares
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-32695000
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32695000
CY2015Q2 us-gaap Sales Revenue Net
SalesRevenueNet
150000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-33013000
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
318000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-94000
CY2015Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-68000
CY2015Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
267000
CY2015Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
240000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
33163000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27006000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6157000
CY2015Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
-51000

Files In Submission

Name View Source Status
0001193125-15-283822-index-headers.html Edgar Link pending
0001193125-15-283822-index.html Edgar Link pending
0001193125-15-283822.txt Edgar Link pending
0001193125-15-283822-xbrl.zip Edgar Link pending
d65681d10q.htm Edgar Link pending
d65681dex311.htm Edgar Link pending
d65681dex312.htm Edgar Link pending
d65681dex321.htm Edgar Link pending
d65681dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kpti-20150630.xml Edgar Link completed
kpti-20150630.xsd Edgar Link pending
kpti-20150630_cal.xml Edgar Link unprocessable
kpti-20150630_def.xml Edgar Link unprocessable
kpti-20150630_lab.xml Edgar Link unprocessable
kpti-20150630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending